

⁹These two authors contributed equally to this work.

¹⁰These two authors contributed equally to this work and serve as co-corresponding authors.

REFERENCES

- Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. *Adv Anat Pathol* 2015; **22**: 29–49.
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R *et al.* The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; **127**: 2375–2390.
- Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S *et al.* Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. *Blood* 2007; **109**: 2156–2164.
- Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD *et al.* Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. *Blood* 2014; **123**: 2915–2923.
- Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I *et al.* Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol* 2010; **28**: 1583–1590.
- Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R *et al.* Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. *Nat Med* 2005; **11**: 623–629.
- Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N *et al.* Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. *Cancer Cell* 2015; **27**: 516–532.
- Velusamy T, Kiel MJ, Sahasrabudhe AA, Rolland D, Dixon CA, Bailey NG *et al.* A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. *Blood* 2014; **124**: 3768–3771.
- Scarfo I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E *et al.* Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. *Blood* 2016; **127**: 221–232.
- Shi W, George SK, George B, Curry CV, Murzabdillaeva A, Alkan S *et al.* TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma. *Mol Oncol* 2017; **11**: 1189–1207.
- Goel RK, Lukong KE. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology. *Cancer Metastasis Rev* 2016; **35**: 179–199.
- Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, Calderaro J *et al.* Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. *Cancer Cell* 2014; **25**: 428–441.
- Hosoya N, Qiao Y, Hangaishi A, Wang L, Nannya Y, Sanada M *et al.* Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. *Genes Chromosomes Cancer* 2005; **42**: 269–279.
- Grill B, Wilson GM, Zhang KX, Wang B, Doyonnas R, Quadroni M *et al.* Activation/division of lymphocytes results in increased levels of cytoplasmic activation/proliferation-associated protein-1: prototype of a new family of proteins. *J Immunol* 2004; **172**: 2389–2400.
- Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA *et al.* ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood* 2014; **124**: 1473–1480.

Supplementary Information accompanies this paper on the Leukemia website (<http://www.nature.com/leu>)

OPEN

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients







Leukemia (2018) **32**, 569–572; doi:10.1038/leu.2017.315

Novel antibody-based therapies for cancer are predictably effective if they can target cancer cells without damaging normal organs.¹ We have developed various recombinant immunotoxins (RITs) against different targets on cancer cell surfaces.² RITs are hybrid proteins that consist of antibody variable fragments attached to a truncated portion of *Pseudomonas* Exotoxin A (PE). Several immunotoxins are currently in clinical trials or preclinical development.^{2–4} We have reported previously that immunotoxin moxetumomab pseudotox targeting CD22 produces complete remissions in many patients with refractory hairy cell leukemia.⁵ This agent has recently completed a phase 3 trial. In addition, a RIT that targets mesothelin showed promising clinical responses in patients with chemotherapy-resistant malignant mesothelioma.⁴

Multiple myeloma (MM) is a B-cell malignancy that originates in the bone marrow (BM). Although there are FDA-approved antibody-based therapies available for the treatment of some B-cell malignancies, no very effective antibody-based therapy is yet available for MM.⁶ The B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor (TNFR) superfamily and is highly expressed in all MM cells from patients.⁷ Because of

the restricted expression of BCMA to plasma cells and its role in growth as well as cell survival of MM, the BCMA antigen has been investigated as the targets in various immunotherapeutic strategies. These include antibody-based therapy,⁸ chimeric antigen receptor therapy⁹ and therapy with BiTEs.¹⁰

To develop immunotoxins that target BCMA we have generated a panel of monoclonal antibodies (mAbs) by immunizing mice with recombinant BCMA protein using hybridoma technology. We produced hybridomas producing anti-BCMA mAbs as described (Supplementary Materials and Methods). Because BCMA, TACI and BAFFR and BCMA share the same natural ligands, we tested the reactivity of each anti-BCMA mAb with two structurally closely-related TNFRs (TACI or BAFFR) expressed on transfected 293 T cells by flow cytometry (Supplementary Figure S1A) and TNFR-rFc fusion proteins by enzyme-linked immunosorbent assay (Supplementary Figure S1B). Based on this analysis, we selected BM24 and BM306 because they bind to BCMA antigen on the cell surface with high affinity and specificity. The binding affinity (KD) of both mAbs are $< 1 \times 10^{-10}$ M. We cloned the VH and the VL from BM24- and BM306-expressing hybridomas using IgG1 isotype-specific oligo primers¹¹ and used the LR version of the PE toxin.¹² A schematic of the Fab-immunotoxin protein and genes



encoding the immunotoxins is shown (Supplementary Figure S1C and D). After expression and purification, we obtained highly purified RITs for both BM24 and BM306. The corresponding immunotoxins are named LMB38 and LMB70, respectively. A

sodium dodecyl sulfate gel showing that the immunotoxins are highly purified is shown (Supplementary Figure S1E).

We tested the cytotoxic activity of LMB38 and LMB70 on BCMA expressing cell lines using a cell proliferation assay (WST-1).

Figure 1. Activity of anti-BCMA immunotoxin LMB70. (a) Representative cytotoxicity assay on BCMA-positive cells using WST8 reagent after three days incubation with RIT. (b) Cell viability assay using Flow cytometry analysis. BCMA expressing H929 cells are incubated with 100 ng/ml of LMB70 for indicated time, washed three times and incubated further with complete media. Three days after seeding, cells were stained with Annexin V PE and 7-ADD and cell viability was analyzed using flow cytometry. Annexin V- and 7AAD-negative cells were considered viable. (c) Normalized viability of myeloma plasma cells, identified as illustrated in Supplementary Figures S2A and B. Cells were incubated with different concentrations of LMB70 for 3 days and viability was measured using 7AAD. (d) IC₅₀ value of LMB70 on myeloma plasma cells from different myeloma patients and from myeloma cell lines. (e) Antitumor activity of LMB70 on BCMA expressing H929 xenograft ($P < 0.001$ for LMB70 vs PBS on day 17). (f) Antitumor activity of LMB70 and Abraxane combination on BCMA expressing H929 xenograft ($P < 0.001$ for Combo vs LMB70 and $P < 0.002$ for Abrx on day 19).

Table 1. Activity of LMB38 and LMB70 on BCMA-positive cell determined by 3 days WST assay

Cell line	Cell type	IC ₅₀ (ng/ml)			
		LMB38	LMB70	RG7787	BM306
U266B	Myeloma	1.9 ± 0.2	5.0 ± 0.4	> 1000	> 1000
H929	Myeloma	1.2 ± 0.3	1.1 ± 0.2	> 1000	> 1000
RPMI-8226	Myeloma	6.9 ± 0.8	5.1 ± 0.4		> 1000
LP-1	Myeloma	25.0 ± 2	20.0 ± 2		
JJN3	Plasma cell leukemia	2.5 ± 0.8	4.0 ± 0.6		> 1000
Jeko-1	Mantle cell Lymphoma				
		> 100	> 100		
HUT-102	T-cell lymphoma	> 100	> 100		
<i>Cells from patient</i>					
MM-165	Myeloma		0.4		
MM-180	Myeloma		17.0		
MM-186	Myeloma		2.3		
MM-186 Relapse	Myeloma		1.0		
MM-192	Myeloma		17.9		
MM-088	Myeloma		1.0		
MM-197	Myeloma		6.0		
MM-199	Myeloma		4.3		

Representative cell-killing curves are shown for LMB70 (Figure 1a) and LMB38 (Supplementary Figure S1F). The IC₅₀ values are summarized in Table 1. The IC₅₀ of LMB38 on H929, U266B, JJN3, RPMI-8226, LP-1 and KMS-18 are 1.2, 1.9, 2.5, 6.9, 25 and 55 ng/ml, respectively. Similarly, the IC₅₀ values for LMB70 on those cell lines are 1.1, 5.0, 4.0, 5.1, 20 and 65 ng/ml, respectively. LMB38 and LMB70 have no activity on Jeko-1 and the HUT-102 cell line that is BCMA negative.

Because WST-1 assays measure both cell growth inhibition and cell death, we measured the cell killing by flow cytometry in which Annexin V and 7AAD staining was simultaneously used to analyze apoptosis and cell death at the same time. Over 95% of cells were Annexin V/7AAD positive when exposed to LMB70 for only 10 min, indicating a very short exposure to LMB70 is sufficient to kill almost all of the antigen-positive target cells (Figure 1b).

To determine whether LMB70 would kill cells from patients with MM, we analyzed BMMNCs from seven patients with active disease who had considerable numbers of myeloma plasma cells in the BM. A summary of the activity results with all patients analyzed are shown (Figure 1c, 1d and Table 1). Typical cell analysis results for three patients are shown in Supplementary Figure S2A and B. The myeloma plasma cells of all patient samples were killed by LMB70 in a dose-dependent manner as shown (Figure 1c) but not the non-myeloma by standard cells (Supplementary Figure S2C). Figure 1d shows that the IC₅₀ values for the MM cell lines varied between 0.4 and 18 ng/ml and the IC₅₀ values of myeloma plasma cells from patients were in the same range as from myeloma cell lines.

To determine whether the apoptosis pathway is induced after exposure of H929 cells to LMB70, we performed western analysis of proteins involved in apoptosis. As shown in Supplementary Figure S2D, the level of Mcl-1 and Bcl-XL was markedly diminished after 6-h exposure of immunotoxin. Also, Caspase 3, 8 and 9 underwent cleavage during the 6-h period. These changes are consistent with rapid induction of apoptosis.

Next, we grew tumor in severe combined immunodeficient (SCID) mice using the most sensitive cell line H929 to test *in vivo* efficacy of LMB38 and LMB70 in mice. Based on mouse safety data of other previous immunotoxins, we treated mice with 1.5 mg/kg every other day × 5 doses. As shown for LMB70 (Figure 1e) and LMB38 (Supplementary Figure S2E), the growth of tumors in immunotoxin treated groups are delayed or the tumors decrease in size up to 50%, but they grew back once the treatment was stopped. We used the H929 cell line for animal studies because it grows in SCID mice and develops uniform tumors when injected subcutaneously with matrigel. We found that both LMB38 and LMB70 caused tumors to shrink and slowed tumor progression but alone did not produce a complete response, although both are very active on H929 cells *in vitro*. The basis of the incomplete responses is being studied but is not owing to antigen loss, and cells isolated from treated tumors are fully responsive when returned to cell culture.

Paclitaxel, an anti-microtubule agent that promotes microtubule assembly has been studied in MM as a chemotherapeutic agent. Nab-paclitaxel (Abraxane) is a modified version of paclitaxel that has distinct pharmacologic properties with greater uptake by and retention within tumors which made it efficacious against some solid tumors. Several clinical studies have reported modest response by paclitaxel as a single agent in patients with newly diagnosed MM.¹³ A recent phase II trial of nab-paclitaxel in patients with relapse of refractory MM showed 15% (2/13) overall response rate.¹⁴ We also previously found that the combination of immunotoxin and a taxane acted synergistically to cause complete regressions of mesothelin expressing malignancies (cancers of cervix, pancreas and stomach).¹⁵ Therefore, we treated H929 xenograft bearing mice with LMB70 and Abraxane. The combination of Abraxane (20 mg/kg) and LMB70 (1 mg/kg) gave complete remissions that lasted over 30 days (Figure 1f), whereas each agent alone did not. These doses of drug were well tolerated with no loss of weight in the treated mice (Supplementary Figures 3A-D).

In summary, we have produced two RITs that kill myeloma cell lines and produce complete remissions in mice with myeloma tumors. Our data suggest that further preclinical development of the agents for myeloma therapy is warranted.

CONFLICT OF INTEREST

IP is an inventor on several patents on immunotoxins that have all been assigned to the NIH. The remaining authors declare no conflict of interest.

TK Bera^{1,5}, Y Abe^{2,5,6}, T Ise^{2,7}, A Oberle³, D Gallardo⁴, X-f Liu¹, S Nagata^{2,7}, M Binder³ and I Pastan¹

¹Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology Research, Bethesda, MD, USA;

²Center, Sanford Research, Sioux Falls, SD, USA;

³Klinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany and

⁴Leidos Biomedical Research, Inc., National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

⁵These authors contributed equally to this work.

⁶Current address: Division of Drugs, National Institute of Health Sciences, Setagaya, Tokyo 1588501, Japan.

⁷Current address: Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 5670085, Japan.

E-mail: pastani@mail.nih.gov

REFERENCES

- 1 Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. *Cancer Immunol* 2012; **12**: 14.
- 2 Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. *Annu Rev Med* 2007; **58**: 221–237.
- 3 Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrok C, Steinberg SM *et al*. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22 positive hematologic malignancies of childhood: pre-clinical studies and Phase I clinical trial. *Clin Cancer Res* 2010; **16**: 1894–1903.
- 4 Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A *et al*. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. *Sci Transl Med* 2013; **5**: 208ra147.
- 5 Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M *et al*. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. *J Clin Oncol* 2012; **30**: 1822–1828.
- 6 Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J *et al*. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and borte-zomib: a multicenter international myeloma working group study. *Leukemia* 2012; **26**: 149–157.
- 7 Laabi Y, Gras MP, Carbonnel F, Brouet JC, Berger R, Larsen CJ *et al*. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. *EMBO J* 1992; **11**: 3897–3904.
- 8 Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A *et al*. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood* 2014; **123**: 3128–3138.
- 9 Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S *et al*. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin Cancer Res* 2013; **19**: 2048–2060.
- 10 Ramadoss NS, Schulman AD, Choi SH, Rodgers DT, Kazane SA, Kim CH *et al*. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. *J Am Chem Soc* 2015; **137**: 5288–5291.
- 11 Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. *Methods Mol Biol* 2004; **248**: 503–518.
- 12 Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ *et al*. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. *Blood* 2009; **113**: 3792–3800.
- 13 Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Group Study (E1A93). *Am J Clin Oncol* 1998; **21**: 553–556.
- 14 Jain T, Dueck AC, Kosiorek HE, Ginos BF, Mayo A, Reeder CB *et al*. Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. *Am J Hematol* 2016; **91**: E504–E505.
- 15 Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. *Mol Cancer Ther* 2014; **13**: 2653–2661.



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

© The Author(s) 2018